Charlotte Henderson
Co-Founder & Chief Executive Officer RevoNA Bio
Dr Charlotte Henderson is Co-founder and CEO of RevoNA Bio, where she leads the development of innovative technologies for RNA-targeted drug discovery. With expertise in RNA biochemistry and therapeutic discovery, she has been instrumental in building RevoNA’s platform and advancing its application to previously inaccessible disease targets. Charlotte combines experience across academic research and biotechnology, with a particular interest in translating advances in RNA science into new therapeutic opportunities. Her work focuses on expanding the scope of drug discovery through the identification of small molecules that selectively target RNA.
Seminars
Wednesday 11th November 2026
Using Scalable RNA Screening to Accelerate RNA-Targeted Drug Discovery
9:00 am
- Moving beyond case-by-case RNA discovery by developing scalable screening workflows that identify functional RNA structures and tractable targets earlier
- Comparing fragment-based, affinity-based, and cell-based screening approaches to determine which technologies generate actionable RNA-targeted hits
- Prioritizing functional output over binding alone to reduce false positives and identify compounds with meaningful RNA-modulating activity
